Clinical trial reveals positive results for treating children with rare gliomas
Tafinlar and Mekinist led to a 56% overall response rate in children with BM-HGG
Read Moreby Jen Brogan | Nov 28, 2023 | News | 0
Tafinlar and Mekinist led to a 56% overall response rate in children with BM-HGG
Read Moreby Lucy Parsons | Sep 17, 2020 | News | 0
Over half of patients treated with combination therapy were alive and relapse-free after five years
Read Moreby Selina McKee | Oct 18, 2018 | News | 0
The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available to eligible skin cancer patients, after cost regulators published guidance backing funds for the treatment.
Read Moreby Selina McKee | Sep 17, 2018 | News | 0
The National Institute for Health and Care Excellence has backed NHS funding for Novartis’ oral targeted adjuvant combination therapy Tafinlar and Mekinist, offering new hope to patients with a specific type of skin cancer.
Read Moreby Selina McKee | Oct 24, 2017 | News | 0
A targeted combination therapy being developed by Novartis as adjuvant treatment for patients with a certain type of melanoma has been assigned breakthrough designation in the US.
Read Moreby Selina McKee | Jun 23, 2017 | News | 0
Novartis’ combination therapy Tafinlar + Mekinist has won approval from the US Food and Drug Administration to treat patients with metastatic non-small cell lung cancer (NSCLC) carrying the BRAF V600E mutation.
Read Moreby Selina McKee | Jun 6, 2017 | News | 0
Novartis and Bristol-Myers Squibb have signed a clinical research pact to investigate the safety, tolerability, and efficacy of combining their respective drugs Mekinist and Opdivo.
Read Moreby Selina McKee | Apr 3, 2017 | News | 0
European regulators have expanded the scope of Novartis’ Tafinlar/Mekinist combination to include the treatment of patients with a certain form of lung cancer.
Read Moreby Selina McKee | Sep 13, 2016 | News | 0
Three new medicines have been endorsed for routine use on the NHS giving patients new options for skin cancer, chronic myeloid leukaemia, and anticoagulant reversal.
Read Moreby Selina McKee | Jun 22, 2016 | News | 0
NICE has published new guidelines endorsing NHS use of five medicines, widening treatment options for some patients with lung cancer, high cholesterol, melanoma and the skin condition hidradentitis.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
